Mumbai based science led nutrition company Ace Blend has raised $9.91 million, about Rs 95 crore, in a Series A2 funding round led by 3one4 Capital.
Existing investor Fireside Ventures increased its investment in the round, after leading Ace Blend’s $3.3 million pre-Series A round in August 2025.
The company announced the round on 29 October 2026. It plans to spend much of the new capital on proof rather than promotion, with clinical trials, supply chain strength and automated quality testing at the centre of the plan.
Money earmarked for evidence, not advertising
Ace Blend plans to run clinical trials through contract research organisations, with the aim of publishing results in peer reviewed international journals. That is a deliberate choice in a category where product claims often travel faster than evidence.
It also plans automated batch by batch testing for nutritional accuracy, pesticide residues and heavy metals, without human intervention in the testing step. Shelf stability studies at launch and again six months later are meant to build long term safety data for its products.
The remaining priorities are research led product development and supply chain improvements. The company holds issued patents for new nutrition formats designed for everyday use, with the first such products expected in the fourth quarter of FY27.
A founder story that started at home
Ace Blend was founded by Shivam Hingorani, and it made its first sales in 2018 after more than a decade of research. His mother, Anita Raaj, was one of India’s earliest fitness pioneers, and that early exposure shaped how he came to see fitness and nutrition.
Saif Mehkri joined as co-founder in 2022, bringing nearly three decades of experience in the nutrition industry. He helped build a vertically integrated supply chain and open doors to global ingredient partners.
Science built, in the company’s own framing
Ace Blend describes its approach as science built rather than science backed. It says it starts with clinical evidence and lets that evidence decide the nutrient form, the dose and the delivery method, instead of building a product around a popular ingredient.
The company controls sourcing, formulation and manufacturing, while clinical validation and automated testing are handled independently by accredited laboratories in Europe. Its products are developed by an in house clinical team and recommended by a network of more than 400 doctors, the company says.
Global ingredient suppliers DSM and TCI have granted Ace Blend exclusive rights in India to certain technologies, the company says. That exclusivity, if it holds as the range expands, is the kind of moat that is hard for a marketing led rival to copy quickly.
It all comes down to bridging that gap and improving health span in ways people can truly feel.
That is how founder Shivam Hingorani framed the mission, describing a gap between fast changing modern life and human biology that evolves far more slowly.
Growth, range and the target ahead
Ace Blend says it grew 300 percent in FY26, with more than 46 percent of its customers returning to buy again. Its range covers about 14 products across heart health, brain health, sleep, recovery, gut health, strength and immunity, including plant based protein powders, superfood mixes and functional supplements.
The company sells through its own website and through Amazon, Flipkart, Zepto and Blinkit. Its own website accounts for about half of revenue, with the rest coming from marketplaces and other online channels.
The bet fits a wider shift toward food and nutrition brands built around Indian health concerns, a theme KeeVurds explored in its story on Bajo Foods.
It is targeting annual recurring revenue of Rs 250 crore to Rs 300 crore over the next 12 to 18 months, with profitability also in sight. That target will test whether repeat buying and clinical evidence can carry a brand past the point where advertising alone stops working.
3one4 Capital’s portfolio includes Licious, Darwinbox and Kapiva, so Ace Blend sits alongside another Indian wellness brand in the investor’s stable. The distinction Ace Blend is pitching is control over quality and claims, rather than a wider catalogue or louder marketing.
What has to happen next
The test now is publication. Clinical trials that reach peer reviewed journals would give Ace Blend evidence its rivals cannot match with packaging alone. Until then, the funding buys the chance to prove the science, not proof itself.
